SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma Meeting Abstract
| Authors: | Luke, J. J.; Warner, A. B.; Chmielowski, B.; Diab, A.; Gebhardt, C.; Hernandez-Aya, L. F.; Hu-Lieskovan, S.; Karapetyan, L.; Lawrence, D. P.; McKean, M.; Mitchell, T. C.; Moschos, S. J.; Moser, J. C.; Olszanski, A. J.; Patel, S. P.; Schadendorf, D.; Smithy, J. W.; Truong, T. G.; Wermke, M.; Britten, C. |
| Abstract Title: | SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| Start Page: | TPS2673 |
| Language: | English |
| ACCESSION: | WOS:001534399400001 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.TPS2673 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
